DEAL ANNOUNCEMENT / PRESS RELEASE
McDermott Represents Datacore in its Acquisition of Mayadata
November 18, 2021
Read time: 3 min
International law firm McDermott Will & Emery represented Datacore Software Holdings, a Florida-based software-defined storage company and pioneer of the development of SAN virtualization technology, in its acquisition of Mayadata Holdings, a data agility company that offers software to accelerate the building and operations of stateful applications on Kubernetes based clouds.
- The transaction was announced on November 18, 2021.
- McDermott acted as legal counsel to Datacore.
- The McDermott team was led by Brian Gordon and included Sheldon Hughes, Tipanun Bisabultr and Greg Weigand.
- Read Datacore’s press release here.
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices, industries and more than 20 locations to deliver highly effective—and often unexpected—solutions that propel success. More than 1,200 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.
Media Contact
McDermott advises Mainova on majority stake in mobiheat
DEAL ANNOUNCEMENT / PRESS RELEASE
McDermott advises Mainova on majority stake in mobiheat
November 18, 2020
Read time: 3 min
Frankfurt a.M., November 18, 2021 – McDermott Will & Emery has advised Mainova AG on the acquisition of a majority stake in energy service provider mobiheat GmbH.
The transaction will also include mobiheat’s foreign subsidiaries in Austria and Switzerland. The sellers of the shares are Energieversorgung Offenbach AG (EVO) and the mobiheat founders. “There is a lot going on in the energy sector, it’s all about new opportunities, future viability and strategic partnerships – and this is also the case with Mainova AG,” explains Norman Wasse, partner at McDermott.
mobiheat GmbH, headquartered in Friedberg, Bavaria, specializes in mobile heating, cooling, and steam centers in German-speaking countries. By acquiring mobiheat, Mainova will further expand its own energy services business.
The team advising Mainova was led by Frankfurt Corporate/M&A Partner Norman Wasse, and included Partners Kian Tauser (Tax), Christian Krohs (Antitrust, Düsseldorf/Cologne), Gudrun Germakowski (Labor, Düsseldorf), Oliver Hahnelt (Finance), Christian L. Masch (IT/IP, Munich), Maximilian Clostermeyer (Real Estate), Alexa Ningelgen (Public Law, Düsseldorf); Counsel Marcus Fischer (Tax) and Nikolas Koutsós (Finance), as well as Associates Lisa Schickling, Marion von Grönheim (both Corporate/M&A), Carina Kant (Antitrust Law, Düsseldorf/Cologne), Lukas Deutzmann (Labor Law, Düsseldorf/Cologne), Isabella Kätzlmeier (IT/IP, Munich), Franziska Leubner (Labor Law, Munich), Elif Sultan Üzümovali (Public Law, Düsseldorf) and Tina Zeller (Real Estate).
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices, industries and more than 20 locations to deliver highly effective—and often unexpected—solutions that propel success. More than 1,200 lawyers strong, we bring our personal passion and legal prow-ess to bear in every matter for our clients and the people they serve.
Media Contact
McDermott Advises Dynacure on Exclusive Agreement with Nippon Shinyaku
PRESS RELEASE
McDermott Advises Dynacure on Exclusive Agreement with Nippon Shinyaku
November 18. 2021
Read time: 3 min
McDermott Will & Emery is advising Dynacure, a clinical-stage company focused on developing and commercializing innovative therapies to transform the lives of patients with rare diseases who have few or no treatment options, on the signing of a long-term strategic development and commercialization agreement of DYN101 with Nippon Shinyaku Co., Ltd in Japan. Dynacure will retain rights to rest-of-world development and commercialization. Dynacure will receive an initial payment of USD 5 million.
Under the terms of the agreement, Nippon Shinyaku has obtained an exclusive option to acquire development and commercial rights in the territory of Japan from Dynacure to develop DYN101, an investigational antisense oligonucleotide product candidate designed to be a disease-modifying medicine for the treatment of the majority of Myotubular and Centronuclear Myopathies (CNM).
DYN101 is currently being evaluated in a Phase 1/2 clinical trial, UNITE-CNM (DYN101-C101), at multiple clinical sites in Europe. DYN101 has been granted orphan drug designation by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) and rare pediatric disease designation by the FDA. There is currently no FDA-, EMA- or Pharmaceuticals and Medical Devices Agency (PMDA)- approved therapeutic treatment for CNM.
Dynacure was counseled by Emmanuelle Trombe, partner and Katya Ascher, Counsel.
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices, industries and more than 20 locations to deliver highly effective—and often unexpected—solutions that propel success. More than 1,200 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.
Media Contact
Schulte Roth & Zabel Presents Its 12th Annual Shareholder Activism Conference
PRESS RELEASE
Blank Media template
Read time: 2 min
Media Contact
McDermott Represents Ampersand Capital Partners in its Sale of Adaptas Solutions to IMI
DEAL ANNOUNCEMENT / PRESS RELEASE
McDermott Represents Ampersand Capital Partners in its Sale of Adaptas Solutions to IMI
November 17, 2021
Read time: 3 min
International law firm McDermott Will & Emery represented Ampersand Capital Partners, a heathcare-focused private equity firm, in the sale of its portfolio company Adaptas Solutions, a manufacturer of mass spectrometry subsystems and components, to IMI plc, a UK-based engineering specialist.
- The transaction was announced on November 15, 2021.
- McDermott acted as legal counsel to Ampersand Capital Partners.
- Adaptas Solutions will become part of IMI’s Precision Fluid OEM Business Unit within IMI Precision Engineering.
- The McDermott team was led by Kristian Werling and Hunter Sharp and included John Zukin, Jordan Wampler, Alex Ruiz, Emily Mussio, James Ross, David Henry, David Levine, David Neville, Noah Feldman-Greene, Karolien Van der Putten, Jeff Holdvogt, Nick Paul, Jed Gordon, Connor Romm, Mark Bilut, Brian Mead and Anh Lee.
- Read IMI’s release here.
McDermott’s private equity practice is among the top four most active PE law firms globally and in the US with more than 160 dedicated private equity lawyers in 21 locations globally. In addition to being Pitchbook’s top Healthcare PE firm for a fourth consecutive year and fifth in both IT and financial services private equity, we are named Energy & Industrials Law Firm of the Year (Large Cap) by The Deal, Top 10 in PE Buyouts by MergerMarket and Top 10 in US Mid-Market by Bloomberg. Learn more about our PE practice by visiting mwe.com/pe.
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices, industries and more than 20 locations to deliver highly effective—and often unexpected—solutions that propel success. More than 1,200 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.
Media Contact
McDermott Will & Emery Advises Berenberg on the Uplisting of The Social Chain AG
DEAL ANNOUNCEMENT / PRESS RELEASE
McDermott Will & Emery Advises Berenberg on the Uplisting of The Social Chain AG
November 17, 2021
Read time: 3 min
Frankfurt, November 17, 2021 – International law firm McDermott Will & Emery has advised Joh. Berenberg, Gossler & Co. KG in connection with the uplisting of The Social Chain AG, Berlin, from the unregulated market (Open Market) of the Dusseldorf Stock Exchange to the regulated market of the Frankfurt Stock Exchange with simultaneous admission to the sub-segment of the regulated market with additional post-admission obligations (Prime Standard).
The relevant securities prospectus has been approved by the Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin) on 11 November 2021. Approximately 11.5 million shares of The Social Chain AG have been traded in the Prime Standard of the Frankfurt Stock Exchange since 12 November 2021. Further approximately 2.9 million shares are to be issued in December through a capital increase in kind.
The McDermott team was led by partners Simon Weiß and Joseph Marx, Associates Christoph Schäfer and Isabelle Müller also advised (all Capital Markets, all Frankfurt).
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices, industries and more than 20 locations to deliver highly effective—and often unexpected—solutions that propel success. More than 1,200 lawyers strong, we bring our personal passion and legal prow-ess to bear in every matter for our clients and the people they serve.
Media Contact
McDermott Represents Gemspring Capital Management in its Acquisition of AINS
DEAL ANNOUNCEMENT / PRESS RELEASE
McDermott Represents Gemspring Capital Management in its Acquisition of AINS
November 15, 2021
Read time: 4 min
International law firm McDermott Will & Emery represented Gemspring Capital Management, LLC, a Connecticut-based private equity firm, in its majority interest acquisition of AINS, a leading global provider of cloud-based, adaptive case management platforms and solutions for government and commercial markets.
- The transaction was announced on November 8, 2021.
- McDermott acted as legal counsel for Gemspring.
- McDermott also handled the negotiation, documentation and execution of a senior secured credit facility with MS Private Credit Administrative Services, LLC, a Morgan Stanley affiliate, as the administrative agent and City National Bank, N.A., as revolving agent, provided to AINS in connection with the acquisition.
- The McDermott team was led by Frank Steinherr, Lindsey Reighard, Daniel Layfield, Emily Jewell and Matthew Stern and included Alex Ruiz, Kevin Hall, Emily Mussio, Jed Gordon, Sarah Engle, Carol Spink, Dawn Peacock, Nick Paul, Philip Fitzpatrick, Scott Weinstein, Stacey Callaghan, James Kim, Llewelyn Engel, Vanessa Barmack, Daphne Trotter, Colin Stalter and Scott Regan. The McDermott finance team included Anh Lee, Riley Orloff, Max Brady, Libby Jacobson and Robin Riley.
- Read Gemspring’s press release here.
McDermott’s private equity practice is among the top four most active PE law firms globally and in the US with more than 160 dedicated private equity lawyers in 21 locations globally. In addition to being Pitchbook’s top Healthcare PE firm for a fourth consecutive year and fifth in both IT and financial services private equity, we are named Energy & Industrials Law Firm of the Year (Large Cap) by The Deal, Top 10 in PE Buyouts by MergerMarket and Top 10 in US Mid-Market by Bloomberg. Learn more about our PE practice by visiting mwe.com/pe.
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices, industries and more than 20 locations to deliver highly effective—and often unexpected—solutions that propel success. More than 1,200 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.
Media Contact
McDermott Represents Solaris Health in its Transaction with Michigan Institute of Urology
DEAL ANNOUNCEMENT / PRESS RELEASE
McDermott Represents Solaris Health in its Transaction with Michigan Institute of Urology
November 15, 2021
Read time: 3 min
International law firm McDermott Will & Emery represented Solaris Health, in its transaction with Michigan Institute of Urology (MIU), one of the largest independent urologic sub-specialty groups in the United States, with 19 offices located throughout southeast Michigan.
- The transaction was announced on November 8, 2021.
- McDermott Will & Emery LLP served as legal counsel to Solaris.
- MIU becomes the third Midwestern urology practice this year to join Solaris, following Chicago-based Associated Urological Specialists (AUS) in March and Advanced Urology Associates (AUA), Joliet, IL, in October.
- The McDermott team was led by Joel Rush and Alexander Clavero and included Joe Parise, Maria Navarro, Michael Hacker, Elaine Kao, Nora Klein, Brian Ingram, Allison Wilkerson, Chelsea Rutherford, Nick Alarif, Li Wang, Margaret Cremin, Abigail Kagan, Kevin Hall, and Dan Zucker.
-
- Read Solaris’ press release here.
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices, industries and more than 20 locations to deliver highly effective—and often unexpected—solutions that propel success. More than 1,200 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.
Media Contact
McDermott Advises Acticor Biotech on its Initial Public Offering
PRESS RELEASE
McDermott Advises Acticor Biotech on its Initial Public Offering
November 12, 2021
Read time: 3 min
McDermott has advised Acticor Biotech, a clinical stage biopharmaceutical company dedicated to developing a drug for the treatment of cardiovascular emergencies, on its initial public offering and the first trading of its shares on Euronext Growth Paris, which took place on November 1, 2021.
Acticor Biotech is developing an innovative drug, glenzocimab, for the treatment of the acute phase of ischemic stroke and other cardiovascular emergencies.
Following the open price offer and the global placement, Acticor Biotech realized a capital increase of EUR 15.5 million.
Acticor Biotech’s IPO is chiefly intended to provide the company with financial means to continue its research and development operations in the context of the final objective of marketing its drug candidate, glenzocimab.
The McDermott team that advised Acticor Biotech comprised:
- David Revcolevschi, partner, Louis Feuillée, Théa Delhaye and Mélanie Chailloleau, associates, on corporate aspects;
- Emmanuelle Trombe, partner, and Caroline Noyrez, associate, on Life Sciences aspects;
- Côme de Saint-Vincent, Counsel, on tax aspects.
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices, industries and more than 20 locations to deliver highly effective—and often unexpected—solutions that propel success. More than 1,200 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.
Media Contact
McDermott Advises Apposite Capital On Acquisition Of Italian Leader In Advanced Microscopy Systems – CrestOptics
DEAL ANNOUNCEMENT / PRESS RELEASE
McDermott Advises Apposite Capital On Acquisition Of Italian Leader In Advanced Microscopy Systems – CrestOptics
November, 11, 2021
Read time: 3 min
International law firm McDermott Will & Emery advised Apposite Capital, the healthcare specialist private equity investor, on its acquisition of a majority shareholding in CrestOptics, a world leader in the development and manufacture of advanced systems for fluorescence microscopy from XYence Capital SGR S.p.A. and management. As part of the transaction, the early-stage diagnostics research programmes that CrestOptic has been conducting with Istituto Italiano di Tecnologia (IIT) in the fields of cancer, Alzheimer’s disease and point of care virus detection have been spun off into a sister company, D-TAILS.
CrestOptics is a world leader in scientific optical instrumentation for Fluorescence Microscopy. It has been founded in 2009 by a team of people with a long and proven experience in scientific research, industrial design and manufacturing of electrooptical systems. The mission of the company is the production of state of art instruments using optical and electrooptical technology for scientific and industrial applications.
Apposite Capital is an independent investment firm focused exclusively on healthcare. It backs companies operating in health and social care, medtech & medical products, pharmaceuticals & life sciences and digital health.
McDermott’s cross-border team was led by counsel Calum Thom and included partner Fabrizio Faina, supported by associates Simona Siciliani, Stefano Pardini and trainee solicitor Lucio Caruso, in Milan.
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices, industries and more than 20 locations to deliver highly effective—and often unexpected—solutions that propel success. More than 1,200 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.
